This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Introduction Atrialfibrillation is the most prevalent sustained arrhythmia worldwide and is expected to increase substantially within the coming years. Eligible patients are randomised 1:1 to either a combined supervised and eHealth-based exercise intervention or usual care for 12 months.
Background Hypertrophic cardiomyopathy (HCM) is commonly associated with atrialfibrillation (AF), but its impact on outcomes in real-world practice is uncertain. The aim of the study was to evaluate the clinical profile and prognosis of patients with HCM and AF. Methods Overall, 1739 adult patients with HCM (40.9%
Atrialfibrillation (AFib) is a common heart rhythm disorder characterized by an irregular and often rapid heartbeat. What is AtrialFibrillation? Symptoms of AtrialFibrillation Symptoms vary among individuals. Consulting a local cardiologist is crucial for the proper diagnosis and management of AFib.
This review provides information about the current evidence-base for screening for atrialfibrillation (AF). Finally, novel methods to refine the population to whom AF screening should be offered, which may improve clinical and cost-effectiveness, are considered.
Nature Reviews Cardiology, Published online: 28 February 2024; doi:10.1038/s41569-024-01004-2 Atrialfibrillation is the most common sustained arrhythmia and imposes a substantial burden on patients and health-care providers.
This study investigates the relationship between triglyceride-glucose (TyG) index trajectories and the results of ablation in patients with stage 3D atrialfibrillation (AF).
BackgroundInstant atrialfibrillation termination (AFT) during radiofrequency ablation has been suggested as a predictor of prognosis in persistent atrialfibrillation (AF). Baseline characteristics, procedural details, and clinical outcomes were compared between the groups.ResultsA total of 189 patients [65.0
Background Atrialfibrillation (AF) and acute myocardial infarction (AMI) share risk factors and are bidirectionally associated. Several studies found higher risks of outcomes in individuals with both conditions. Whether the risks of outcomes differ according to temporal order of AF and AMI is unclear.
Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrialfibrillation ablation, Musat et al. recommend shortening the blanking period from three months to one. also emphasize the importance of continuous monitoring.
Background The SCN5A gene polymorphism histidine-558-to-arginine (H558R) has been associated with atrialfibrillation (AF) and may affect the therapeutic effects of flecainide. Secondary analyses evaluated the long-term outcomes and compared the prevalence of H558R in the AF cohort to a general population sample (n=3401).
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrialfibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
Ablation index (AI)-guided pulmonary vein isolation (PVI) has enhanced procedural outcomes for atrialfibrillation (AF).1 1 However, patients with persistent AF present higher recurrence rates due to advanced atrial remodeling,2-3 represented by the left atrial low voltage area (LVA), compared to those with paroxysmal AF.
Postoperative atrialfibrillation (POAF) is associated with an increased rate of neurologic events and worse long-term survival, according to a study published online Sept. 11 in the Journal of Thoracic and Cardiovascular Surgery.
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. "The Circulation.
Twelve-month outcomes data from the pilot phase of the admIRE study, which assessed the safety and efficacy of the VARIPULSE Platform among U.S. 1 Among 20 patients who completed the 12-month follow-up visit, 100% achieved acute success from ablation procedures and 80% remained free from atrial arrhythmia recurrence at one year.
Data on long-term effects of catheter ablation versus antiarrhythmic drugs (AAD) on health-related quality of life (HRQoL) and atrialfibrillation (AF) burden are limited.
The collaboration, according to a written statement issued by the company, aims to address challenges in capturing and analyzing cardiac signals to help physicians enhance patient outcomes for atrialfibrillation procedures. Estimates of current and future incidence and prevalence of atrialfibrillation in the U.S.
They included randomised controlled trials that enrolled adults undergoing major cardiac surgeries and reported postpericardiotomy syndrome, pericardial effusion and pericarditis as primary or secondary outcomes. Beta-blockers probably prevent atrialfibrillation with a large magnitude of effect (RR 0.4, 95% CI 0.20
Using a wearable device, such as a smart watch, to track health data and symptoms, is supposed to help people monitor their health and address symptoms as quickly as possible to spur positive health outcomes.
This high incidence of cognitive decline in AF patients may result from various mechanisms, including reduced cerebral perfusion, microembolism, decreased cardiac output, and chronic inflammation.MethodsThis review synthesizes current evidence on the relationship between AF and cognitive impairment, examines underlying mechanisms of cognitive decline (..)
The primary outcomes of interest were mortality in ventricular and atrial arrhythmias, and later diagnosis of cardiac disease in atrial arrhythmias. The presence of atrialfibrillation (AF) during stress testing was not associated with mortality at all time points: OR 1.53 (95% CI 0.05, 50.19), p=0.81.
Introduction Catheter ablation is an effective and safe strategy for treating atrialfibrillation patients. Nevertheless, studies on the long-term outcomes of catheter ablation in patients with dilated cardiomyopathy are limited. Among the catheter ablation group, 58.7% ( n = 27) had persistent atrialfibrillation.
Atrialfibrillation is the most common cardiac arrhythmia worldwide with around 59 million people concerned in 2019. Researchers have recently developed a deep-learning model capable of predicting the transition from a normal cardiac rhythm to atrialfibrillation.
Background Efforts to maintain sinus rhythm in patients with persistent atrialfibrillation (PsAF) remain challenging, with suboptimal long-term outcomes. Methods All patients undergoing convergent PsAF ablation at our centre were retrospectively analysed.
Additional rhythm-control strategies are frequently continued after index ablation for atrialfibrillation (AFib), according to a study published Feb. 12 in JACC: Clinical Electrophysiology.
BackgroundAn increased risk of recurrent stroke is noted in patients with atrialfibrillation despite direct oral anticoagulant (DOAC) use. 0.45] for rivaroxaban), and a 69% to 83% reduced risk of net composite outcomes (aHR, 0.25 [95% CI, 0.18–0.35] 0.39] for apixaban, 0.23 [95% CI, 0.14–0.37] 0.41] for rivaroxaban).ConclusionsIn
What is the prevalence of subclinical atrialfibrillation (AF) in patients with heart failure and preserved ejection fraction (HFpEF), and how does it impact outcomes?
BackgroundThe incidence and type of complications following catheter ablation of atrialfibrillation have been extensively examined, but the impact associated with these complications on the length of stay and hospitalization costs is unknown.Methods and ResultsThis cohort study included 20 117 adult patients (mean age 62.6±11.4 years,
Initial causality was assessed by inverse variance weighting (IVW), followed by sensitivity analyses using MR-Egger regression, weighted median, and Multiple Effectiveness Residual Sums and Outliers (MR-PRESSO) method.
The term ‘epidemic’ is increasingly used to describe the rising global prevalence of atrialfibrillation (AF). Indeed, numerous studies are currently investigating the impact of such approaches on clinical outcomes and healthcare utilisation. Recent estimates suggest that AF accounts for between 0.9% 2 Before the.
BackgroundThe effectiveness of statin use in preventing adverse cardiovascular events in individuals with atrialfibrillation (AF) has remained uncertain. Journal of the American Heart Association, Volume 13, Issue 24 , December 17, 2024.
(MedPage Today) -- For patients undergoing catheter ablation for atrialfibrillation (Afib), there was no signal that a brief course of colchicine reduced atrial arrhythmia recurrence or improved clinical outcomes when taken for 10 days starting.
Atrialfibrillation (AF) represents the most common cardiac arrhythmia with significant morbidity and mortality implications. This review aims to analyze the existing literature on the effects of dietary modifications on the incidence, progression, and outcomes of atrialfibrillation.
2 Therefore, early identification of HF in high-risk populations, particularly post-MI, is essential for improving outcomes. Common predictors include older age, prior hypertension, diabetes and atrialfibrillation. Risk factors for developing HF after MI vary and are influenced by whether the patient has HFrEF or HFpEF.
The primary efficacy and safety outcomes were stroke or systemic embolic events (stroke/SEE) and major bleeding, respectively; secondary outcomes were ischemic stroke/SEE, intracranial hemorrhage, death, and the net clinical outcome (stroke/SEE, major bleeding, or death). Each outcome was examined across BMI and BW.
Atrialfibrillation catheter ablation (AFCA) improved clinical outcomes compared with medical treatment alone, and early AFCA was associated with better outcomes than late AFCA, particularly decreased risk of heart failure (HF) hospitalization and atrialfibrillation (AFib) recurrence.
Patients with atrialfibrillation, particularly older patients, are frequently at a high risk of bleeding. In patients with atrialfibrillation, abelacimab reduced rates of bleeding relative to rivaroxaban regardless of bleeding risk, with greater absolute safety benefit in those at higher bleeding risk.
The triglycerideglucose (TyG) index, an emerging surrogate marker of insulin resistance, has been implicated in adverse cardiovascular outcomes. However, its prognostic value in critically ill patients with a.
Abstract Introduction Some previous studies have reported that a first-step ethanol infusion into the vein of Marshall (EIVOM) with touch-up radiofrequency (RF) ablation can facilitate mitral isthmus (MI) block and improves the ablation outcomes in persistent atrialfibrillation (PeAF) patients. 0.78, p = .006).
Introduction Three recent randomised controlled trials have demonstrated that pulmonary vein isolation as an initial rhythm control strategy with cryoablation reduces atrial arrhythmia recurrence in patients with symptomatic paroxysmal atrialfibrillation (PAF) compared with antiarrhythmic drug (AAD) therapy.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content